Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: Report on baseline data from the Chronic GVHD Consortium

Moffitt Cancer Center, Tampa, FL, USA.
Blood (Impact Factor: 10.43). 02/2011; 117(17):4651-7. DOI: 10.1182/blood-2010-11-319509
Source: PubMed

ABSTRACT Quality of life (QOL) after hematopoietic cell transplantation (HCT) is compromised by chronic GVHD. In a prospectively assembled multicenter cohort of adults with chronic GVHD (n = 298), we examined the relationship between chronic GVHD severity defined by National Institutes of Health (NIH) criteria and QOL as measured by the SF-36 and FACT-BMT instruments at time of enrollment. Chronic GVHD severity was independently associated with QOL, adjusting for age. Compared with population normative data, SF-36 scores were more than a SD (10 points) lower on average for the summary physical component score (PCS) and role-physical subscale, and significantly lower (with magnitude 4-10 points) for several other subscales. Patients with moderate and severe cGVHD had PCS scores comparable with scores reported for systemic sclerosis, systemic lupus erythematosus, and multiple sclerosis, and greater impairment compared with common chronic conditions including diabetes, hypertension, and chronic lung disease. Moderate to severe cGVHD as defined by NIH criteria is associated with significant compromise in multiple QOL domains, with PCS scores in the range of other systemic autoimmune diseases. Compromised QOL provides a functional assessment of the effects of chronic GVHD, and may be measured in cGVHD clinical studies using either the SF-36 or the FACT-BMT.

  • Source
    • "Response to treatment should be documented at each clinic visit and formal staging by NIH criteria (Filipovich et al, 2005) should be recorded every 3 months. It has been shown that quality of life can be severely affected in patients with cGvHD and it is important to make a formal assessment of quality of life using a validated questionnaire (Pidala et al, 2011). Suitable questionnaires for adult patients include the FACT-BMT, SF-36 questionnaire, EORTC QLQ-C30 and the Lee cGvHD symptom scale (McQuellon et al, 1997; Kopp et al, 2000; Lee et al, 2002b; Pidala et al, 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology and the British Society for Bone Marrow Transplantation has reviewed the available literature and made recommendations for the supportive care and management of organ-specific complications of chronic graft-versus-host disease (cGvHD). This guideline includes recommendations for the specific therapy of skin, oral, liver, gut, lung, ocular and genital manifestations of cGvHD and for the supportive care of these patients, including vaccinations and prophylaxis against infection. The goal of treatment should be effective control of GvHD while minimizing the risk of toxicity and relapse.
    British Journal of Haematology 04/2012; 158(1):62-78. DOI:10.1111/j.1365-2141.2012.09131.x · 4.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Seule perspective de guérison de certaines hémopathies malignes, l’allogreffe de cellules souches hématopoïétiques comporte des risques de morbimortalité significatifs. La morbidité est notamment liée à l’incidence de la réaction du greffon contre l’hôte (graft versus host disease, GVHD). Quand elle n’engage pas le pronostic vital des patients, cette réaction a un impact important sur la qualité de vie des patients. Ses répercussions physiques affectent l’image corporelle, l’image et l’estime de soi. Les retentissements psychiques dépassent la symptomatologie anxieuse ou dépressive, puisque cette GVHD viendra altérer le processus d’intégration psychique de la greffe et les remaniements identitaires qu’elle peut induire.
    Psycho-Oncologie 03/2013; 7(1). DOI:10.1007/s11839-013-0403-9 · 0.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The 2005 National Institute of Health Chronic Graft-versus-Host Disease Consensus Conference recommended collection of patient-reported outcomes in clinical trials on chronic graft-versus-host disease. We assessed whether changes in chronic graft-versus-host disease severity, determined using National Institute of Health criteria, clinicians' assessment or patients' self-evaluation, correlated with patient-reported quality of life as measured by the Short Form-36 and Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) instruments. Three-hundred and thirty-six adult patients (median age 52 years; range, 19-79) with chronic graft-versus-host disease from six transplant centers contributed baseline and follow-up data (from 936 visits overall). While the majority of the patients had stable chronic graft-versus-host disease, improvement or worsening was noted in approximately 40% of follow-up visits. Multivariable analysis demonstrated no association between change in chronic graft-versus-host disease severity evaluated by National Institute of Health criteria and change in quality of life, while clinician-reported changes in severity were associated with changes in some quality of life measures. Patient-reported changes in the severity of chronic graft-versus-host disease were associated with changes in all quality of life measures. Comparison of the Short Form-36 and the FACT-BMT suggested that the data collected in the Functional Assessment of Cancer Therapy-General (FACT-G) core survey are sufficient without the need for the Short Form-36 or the FACT-BMT subscale. We conclude that serial National Institute of Health and clinician-reported chronic graft-versus-host disease severity assessments cannot substitute for patient-reported outcomes in clinical trials. Collection of just the FACT-G instead of the Short Form-36 and the full FACT-BMT will decrease respondent burden without compromising quality of life assessment.
    Haematologica 06/2011; 96(10):1528-35. DOI:10.3324/haematol.2011.046367 · 5.87 Impact Factor
Show more